All In Biotech

Drug Trial Radar · NCT04956692

Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metastatic Squamous or Nonsquamous Non-Small-Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 531 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

531

Actual

Start

Aug 5, 2021

Primary completion

Apr 4, 2023

Study completion Aug 24, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 9, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate pembrolizumab (MK-3475) subcutaneous (SC) administration as the first-line therapy in the treatment of metastatic squamous and nonsquamous NSCLC by assessing the pharmacokinetics (PK), safety, and efficacy of pembrolizumab SC injection in combination with standard-of-care chemotherapy. The primary hypothesis of the study is Pembrolizumab SC is noninferior to pembrolizumab intravenous (IV) for Cycle 1 Area Under Curve (AUC) and Cycle 6 minimal concentration (Ctrough) at steady state. Participants who discontinue study treatment after receiving the first course of 35 administrations of pembrolizumab (approximately up to 2 years) for reasons other than disease progression or intolerability, may be eligible for a second course of pembrolizumab for up to approximately 1 additional year if they have experienced radiographic disease progression per RECIST 1.1 as assessed by BICR after stopping first course treatment.

Conditions

  • Non-Small Cell Lung Cancer

Interventions

  • Pembrolizumab SCBiological

    SC injection

  • Pembrolizumab IVBiological

    IV injection

  • PaclitaxelDrug

    IV injection

  • Nab-PaclitaxelDrug

    IV infusion

  • CarboplatinDrug

    IV infusion

  • CisplatinDrug

    IV infusion

  • PemetrexedDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cycle 1 Area Under The Curve From 0-3 Weeks (AUC 0-3wks) of PembrolizumabTime frame: Cycle 1: predose and postdose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 2: predose day 1. Each cycle is 21 days.
  2. Cycle 6 Model-Based Minimal Concentration (Ctrough) of PembrolizumabTime frame: Cycle 6: predose day 1; days 2, 3, 4, 5, 6, 7, 10, and 15. Cycle 7: predose day 1. Each cycle is 21 days.

Locations

126 sites in 16 countries. Site status is shown where the registry gives one.

  • St. Bernards Medical Center ( Site 0103)

    Jonesboro, Arkansas

  • St Joseph Heritage Healthcare-Oncology ( Site 0102)

    Fullerton, California

  • Cancer Blood and Specialty Clinic ( Site 0105)

    Los Alamitos, California

  • PIH Health Hematology Medical Oncology ( Site 0106)

    Whittier, California

  • Holy Cross Hospital ( Site 0017)

    Fort Lauderdale, Florida

  • Memorial Regional Hospital-Memorial Cancer Institute ( Site 0104)

    Hollywood, Florida

  • Advent Health ( Site 0013)

    Orlando, Florida

  • Fort Wayne Medical Oncology and Hematology ( Site 0101)

    Fort Wayne, Indiana

  • Baptist Health Lexington ( Site 0099)

    Lexington, Kentucky

  • St Luke's Hospital - Kansas City ( Site 0033)

    Kansas City, Missouri

  • St. Vincent Frontier Cancer Center ( Site 0058)

    Billings, Montana

  • Montefiore Medical Center [Bronx, NY] ( Site 0040)

    The Bronx, New York

  • The University of Tennessee Medical Center ( Site 0050)

    Knoxville, Tennessee

  • Tennessee Oncology ( Site 0051)

    Nashville, Tennessee

  • Oncology Consultants, PA ( Site 0052)

    Houston, Texas

  • Millennium Physicians - Oncology ( Site 0097)

    Houston, Texas

  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care ( Site 0100)

    Blacksburg, Virginia

  • West Virginia University ( Site 0056)

    Morgantown, West Virginia

  • HOSPITAL EVANGÉLICO DE CACHOEIRO DE ITAPEMIRIM ( Site 0307)

    Cachoeiro de Itapemirim, Espírito Santo, Brazil

  • Hospital Sao Vicente de Paulo ( Site 0311)

    Passo Fundo, Rio Grande do Sul, Brazil

  • Instituto Joinvilense de Hematologia e Oncologia ( Site 0308)

    Joinville, Santa Catarina, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto ( Site 0305)

    São José do Rio Preto, São Paulo, Brazil

  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0304)

    São Paulo, São Paulo, Brazil

  • Hopital Cochin ( Site 1002)

    Paris, France

  • Nouvel Hôpital Civil (NHC) ( Site 1018)

    Strasbourg, Bas-Rhin, France

  • CHU Limoges CHU Dupuytren ( Site 1011)

    Limoges, Haute-Vienne, France

  • Hôpital Foch ( Site 1019)

    Suresnes, Hauts-de-Seine, France

  • Institut Regional du Cancer de Montpellier - ICM ( Site 1003)

    Montpellier, Herault, France

  • Centre Hospitalier Sud Réunion ( Site 1020)

    Saint-Pierre, La Reunion, France

  • Hopital Guillaume & Rene Laennec ( Site 1007)

    Saint-Herblain, Loire-Atlantique, France

  • Centre Hospitalier de Pau ( Site 1016)

    Pau, Pyrenees-Atlantiques, France

  • CHU de Rouen ( Site 1013)

    Rouen, Seine-Maritime, France

  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0602)

    Guatemala City, Guatemala

  • Clinica Privada Dr. Rixci Ramirez ( Site 0601)

    Guatemala City, Guatemala

  • INTERVASC ( Site 0605)

    Guatemala City, Guatemala

  • Grupo Angeles SA ( Site 0604)

    Guatemala City, Guatemala

  • Centro Regional de Sub Especialidades Médicas SA ( Site 0600)

    Quetzaltenango, Guatemala

  • Semmelweis University-Pulmonológiai Klinika ( Site 1114)

    Budapest, Hungary

  • Orszagos Koranyi Pulmonologiai Intezet ( Site 1104)

    Budapest, Hungary

  • Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1106)

    Kecskemét, Bács-Kiskun county, Hungary

Showing 40 of 126 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.